5 结果
The present invention relates to a new medicament constituted by a new combination for antipsychotic use or, more generally, psychotropic use.
A number of psychotropic agents administered chronically have the disadvantage of inducing in patients an excessive weight gain which is an extremely
The present invention relates to certain novel substituted dihydroimidazo[2,1-b]thiazole and dihydro-5H-thiazolo[3,2-a]pyrimidine compounds which have affinity for 5-HT.sub.1A receptors and which inhibit neuronal reuptake of 5-hydroxytryptamine and/or noradrenaline, to processes for their
The compounds of this invention have the formula ##STR1## in which R is hydrogen or alkyl of from 1 to 5 carbon atoms; R.sub.1 is hydrogen, alkyl of from 1 to 5 carbon atoms, cycloalkylalkyl of from 4 to 8 carbon atoms or aralkyl having from 1 to 5 carbon atoms in the alkyl moiety; X and Y are the
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to the use of an opioid antagonist such as naltrexone in combination with one or more serotonin (5-hydroxytryptamine or 5-HT) or norepinephrine reuptake inhibitor(s) and/or lithium to treat mental or emotional
BACKGROUND OF THE INVENTION
This invention relates to lipid emulsion compositions and to methods of treating systemic toxicity by reducing the bioavailability of pharmaceuticals, poisons and other foreign agents present in the circulation by the intravenous infusion of a lipid emulsion composition.